CD274 and non-small cell lung carcinoma: presented the Phase II cohort results from a clinical trial (KRYSTAL‐1, NCT03785249), which evaluated adagrasib (MRTX849, a KRASG12C inhibitor) in KRASG12C‐mutated nonsmall‐cell lung cancer (NSCLC) previously treated with chemotherapy and antiprogrammed death 1 (PD‐1) or antiprogrammed death ligand 1 (PD‐L1) therapy.